Target intelligence / Profile preview

Mitochondrial uncoupling protein 4 (UCP4)

Target
UCP4
Molecular classification
Transporter, Mitochondrial carrier protein, Mitochondrial anion carrier protein (MACP) family, Solute carrier (SLC) family
01

Overview

Mitochondrial uncoupling protein 4 (UCP4, SLC25A27) is a brain-enriched member of the mitochondrial anion carrier protein (MACP) family that mediates proton leak across the inner mitochondrial membrane, uncoupling oxidative phosphorylation from ATP synthesis and regulating energy dissipation as heat[1][5][3]. UCP4 plays an important role in neuronal cells by modulating the mitochondrial membrane potential, reducing oxidative stress, and protecting against metabolic stress and neurotoxins[3][7]. UCP4 expression is largely restricted to brain tissue and is developmentally regulated. Genetic variants in SLC25A27 have been associated with neurodegenerative conditions, suggesting that UCP4-mediated regulation of mitochondrial function is relevant to diseases such as Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease, and psychiatric disorders[2][3]. No approved drugs directly target UCP4.

Other names
SLC25A27Solute carrier family 25 member 27UNQ772/PRO1566FLJ33552UCP 4uncoupling protein 4
02

Mechanism of action

Not applicable, as no clinically used drug is confirmed to directly target UCP4. Drugs or small molecules would theoretically modulate its uncoupling activity or expression, affecting mitochondrial proton gradient, ROS generation, or neuronal survival.

03

Biological functions

Proton transporter across inner mitochondrial membraneRegulation of mitochondrial membrane potentialModulation of oxidative phosphorylationReduction of reactive oxygen species (ROS)Regulation of energy metabolism and thermogenesisModulation of calcium homeostasisNeuroprotection and adaptation against metabolic and oxidative stress
04

Disease associations

Neurodegenerative disease (e.g., Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia)SchizophreniaLeukoaraiosisMultiple sclerosisIntellectual disability-severe speech delay-mild dysmorphism syndromeEcthyma
05

Safety considerations

Disruption of mitochondrial uncoupling may lead to impaired energy metabolism or increased ROS.Modulation in CNS may impact neuronal function and viability, especially under pathological or stress conditions[3][5]
06

Interacting drugs

None approved or in clinical trials specifically listed as interacting with SLC25A27/UCP4 as of the current literature and database resources[5][6]
07

Biomarkers

Genetic variants of SLC25A27 (e.g., rs9472817 SNP) have been associated with risk of Alzheimer’s disease and frontotemporal dementia[2]

Beyond the preview

Go deeper on Mitochondrial uncoupling protein 4 (UCP4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrial uncoupling protein 4 (UCP4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call